Single centre, open, controlled, randomised (1:1), parallel group: insulin glargine vs. NPH [insulin suspension isophane]: FPG (fasting plasma glucose) in patients with DM type 1 [type 1 diabetes mellitus] who skip the morning meal during treatment with MDI (mulitple daily injection) basal/bolus insulin

Trial Profile

Single centre, open, controlled, randomised (1:1), parallel group: insulin glargine vs. NPH [insulin suspension isophane]: FPG (fasting plasma glucose) in patients with DM type 1 [type 1 diabetes mellitus] who skip the morning meal during treatment with MDI (mulitple daily injection) basal/bolus insulin

Completed
Phase of Trial: Phase IV

Latest Information Update: 13 Oct 2009

At a glance

  • Drugs Insulin glargine; Insulin suspension isophane
  • Indications Type 1 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms SAM
  • Sponsors Sanofi
  • Most Recent Events

    • 07 Jul 2009 Actual initiation date changed from Oct 2001 to Nov 2001 as reported by ClinicalTrials.gov.
    • 13 Sep 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top